NASDAQ:ZURA Zura Bio Q1 2025 Earnings Report $1.91 -0.05 (-2.55%) Closing price 04:00 PM EasternExtended Trading$1.88 -0.03 (-1.57%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Zura Bio EPS ResultsActual EPS-$0.19Consensus EPS -$0.17Beat/MissMissed by -$0.02One Year Ago EPSN/AZura Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AZura Bio Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time7:00AM ETUpcoming EarningsZura Bio's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zura Bio Earnings Headlines3 Penny Stocks With Market Caps Over $70M Worth Watching5 hours ago | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18 at 2:04 AM | finance.yahoo.com“All the land that you see I will give to you and your offspring forever…”“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.July 18 at 2:00 AM | Paradigm Press (Ad)Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of "Buy" from AnalystsJuly 13, 2025 | americanbankingnews.comZura Bio (NASDAQ:ZURA) Stock Price Up 12.5% - Should You Buy?July 10, 2025 | americanbankingnews.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comSee More Zura Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email. Email Address About Zura BioZura Bio (NASDAQ:ZURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation antibody therapies. Headquartered in Cambridge, Massachusetts, the company specializes in the design of mono- and multi-specific antibodies aimed at addressing complex disease biology in oncology, immunology and rare disorders. Zura Bio’s scientific team applies advanced protein engineering techniques to create therapeutic candidates with enhanced stability, specificity and manufacturability. The company’s proprietary antibody platform enables rapid generation and optimization of novel multispecific formats, allowing simultaneous engagement of multiple targets or disease pathways. By fine-tuning antibody architecture, Zura Bio seeks to improve pharmacokinetic properties and reduce off-target effects compared to conventional monoclonal antibodies. This platform underpins a pipeline of preclinical programs designed to tackle immune checkpoint regulation, tumor microenvironment modulation and inflammatory signaling. Zura Bio’s lead programs are advancing through preclinical development, with select candidates poised for IND-enabling studies. The company collaborates with academic laboratories and industry partners to validate target biology and accelerate translational efforts. Through these partnerships, Zura Bio aims to leverage external expertise while retaining full control of its proprietary engineering technologies. Founded by a team of experienced researchers in antibody discovery and development, Zura Bio is committed to addressing unmet medical needs by delivering differentiated therapeutic solutions. The company’s long-term strategy emphasizes clinical proof-of-concept studies in areas with high barriers to treatment, with the goal of improving outcomes for patients who have limited options under current standards of care.Written by Jeffrey Neal JohnsonView Zura Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
